Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Gershenson

Showing results (31-40 of 429) with videos related to

Pageof 43
Sort By:
Gynecologic Oncology|December 8, 2014
Updates and emerging therapies for rare epithelial ovarian cancers: one size no longer fits allReinou S Groen, David M Gershenson, Amanda Nickles Fader
Gynecologic Oncology|October 1, 1984
Second-look laparotomy in fallopian tube carcinomaG L Eddy, L J Copeland, D M Gershenson
British Journal of Cancer|October 21, 2015
Impact of mutational status on survival in low-grade serous carcinoma of the ovary or peritoneumDavid M Gershenson, Charlotte C Sun, Kwong-Kwok Wong
Pharmacoeconomics|August 18, 2000
Pharmacoeconomic considerations in treating ovarian cancerD Bodurka-Bevers, C C Sun, D M Gershenson
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|January 15, 2019
Low grade serous ovarian carcinoma: identifying variations in practice patternsJohn Siemon, David M Gershenson, Brian Slomovitz, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 2, 2021
Fertility preservation in rare ovarian tumorsAnca Chelariu-Raicu, Lauren P Cobb, David M Gershenson
Obstetrics and Gynecology|January 1, 1990
Papillary serous carcinoma of the peritoneumG L Fromm, D M Gershenson, E G Silva
The American Journal of Surgical Pathology|October 26, 2006
The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependentElvio G Silva, David M Gershenson, Anais Malpica, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 24, 1999
Paclitaxel and cisplatin as first-line therapy in recurrent or advanced squamous cell carcinoma of the cervix: a gynecologic oncology group studyP G Rose, J A Blessing, D M Gershenson, et al.
International Journal of Radiation Oncology, Biology, Physics|March 1, 1983
Analysis of the severe complications of irradiation of carcinoma of the cervix: whole pelvis irradiation and intracavitary radiumA D Hamberger, A Unal, D M Gershenson, et al.
Pageof 43

Showing results (31-40 of 429) with videos related to

Sort By:
Pageof 43
Gynecologic Oncology|December 8, 2014
Updates and emerging therapies for rare epithelial ovarian cancers: one size no longer fits allReinou S Groen, David M Gershenson, Amanda Nickles Fader
Gynecologic Oncology|October 1, 1984
Second-look laparotomy in fallopian tube carcinomaG L Eddy, L J Copeland, D M Gershenson
British Journal of Cancer|October 21, 2015
Impact of mutational status on survival in low-grade serous carcinoma of the ovary or peritoneumDavid M Gershenson, Charlotte C Sun, Kwong-Kwok Wong
Pharmacoeconomics|August 18, 2000
Pharmacoeconomic considerations in treating ovarian cancerD Bodurka-Bevers, C C Sun, D M Gershenson
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|January 15, 2019
Low grade serous ovarian carcinoma: identifying variations in practice patternsJohn Siemon, David M Gershenson, Brian Slomovitz, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 2, 2021
Fertility preservation in rare ovarian tumorsAnca Chelariu-Raicu, Lauren P Cobb, David M Gershenson
Obstetrics and Gynecology|January 1, 1990
Papillary serous carcinoma of the peritoneumG L Fromm, D M Gershenson, E G Silva
The American Journal of Surgical Pathology|October 26, 2006
The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependentElvio G Silva, David M Gershenson, Anais Malpica, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 24, 1999
Paclitaxel and cisplatin as first-line therapy in recurrent or advanced squamous cell carcinoma of the cervix: a gynecologic oncology group studyP G Rose, J A Blessing, D M Gershenson, et al.
International Journal of Radiation Oncology, Biology, Physics|March 1, 1983
Analysis of the severe complications of irradiation of carcinoma of the cervix: whole pelvis irradiation and intracavitary radiumA D Hamberger, A Unal, D M Gershenson, et al.
Pageof 43